MHRA: AI Airlock Phase 3 Application Now Open for Medical Devices

• The MHRA has opened applications for Phase 3 of its AI Airlock, a regulatory sandbox for AI enabled medical devices.
• The program's current priority regulatory challenge is Post-Market Surveillance and lifecycle oversight for AI medical devices.
• Applications are accepted year-round, but submissions for the current review wave must be made by October 31st.
• Participants will engage in bespoke testing plans, typically lasting 6-12 months, within the program funded until April 2029.
• The AI Airlock offers a unique opportunity for early regulatory engagement to de-risk product development and ensure compliance.

The MHRA AI Airlock Phase 3 represents a significant opportunity for developers of AI enabled medical devices to proactively engage with the UK's regulatory body in a controlled environment.

The Medicines and Healthcare products Regulatory Agency (MHRA) has officially opened the call for applications for Phase 3 of its AI Airlock program. This initiative invites manufacturers and developers of AI enabled medical devices to participate in a specialized regulatory sandbox designed to evaluate their products and prototypes. The primary goal of this application process is to gather comprehensive information about potential candidates, including details of their AI medical devices, to assess their suitability for engagement within the AI Airlock framework.

The application window for the MHRA AI Airlock Phase 3 application remains open year-round, allowing interested parties to submit their proposals at any time until an official closure announcement is made on the program's dedicated page. Submissions will undergo evaluation in scheduled review waves, with successful applicants being onboarded on a rolling basis. Any applications received after a particular review wave's cutoff will automatically be carried forward for consideration in the subsequent wave. Organizations of all sizes are encouraged to apply, and lead applicants have the flexibility to partner with other companies or entities.

For those aiming to be considered during the current application review wave, a specific deadline of October 31st has been set. However, it is important to note that the application portal will continue to accept submissions beyond this date. A subsequent shortlisting period for later applications is scheduled to occur in Spring 2027, indicating a long-term commitment to the program. The current phase of the AI Airlock is funded through April 2029, providing a substantial timeframe for participants to engage with the regulatory sandbox.

A central focus of the MHRA AI Airlock Phase 3 is to tackle the pressing regulatory challenge of Post-Market Surveillance (PMS) and comprehensive oversight across the entire lifecycle of AI enabled medical devices. The program specifically prioritizes projects that aim to address these critical areas, offering a structured environment for hypothesis development and testing. This emphasis underscores the regulator's commitment to ensuring the ongoing safety and effectiveness of AI technologies once they are deployed in healthcare settings.

While the primary emphasis is on AI medical device Post-Market Surveillance, the MHRA is also receptive to expressions of interest that fall outside these core focus areas. Applicants with alternative regulatory challenges they wish to explore within the UK AI medical device regulatory sandbox are encouraged to submit their proposals, selecting the “Express interest in another regulatory focus area” option on the application form. These broader submissions will play a role in shaping future priorities for the program, although proposals aligned with the current focus on PMS will receive preferential consideration.

Participation in the AI Airlock involves a commitment from candidates to collaborate with the program team for the duration of a bespoke testing plan. This plan, co-developed during the onboarding process, is generally expected to span a period of 6 to 12 months for individual testing and engagement. Following initial applications, some candidates may be invited to a follow-up shortlisting meeting to provide further details about their application, product, and the specific regulatory challenge they intend to test. Confidentiality and commitment agreements will be established between the Airlock program and participating organizations to facilitate this collaborative work.

The MHRA AI Airlock Phase 3 represents a significant opportunity for developers of AI enabled medical devices to proactively engage with the UK's regulatory body in a controlled environment. This UK AI medical device regulatory sandbox allows companies to test and refine their approaches to complex regulatory requirements, particularly those related to Post-Market Surveillance, before their products are widely deployed. Early engagement with the Medicines and Healthcare products Regulatory Agency AI Airlock can help de-risk product development, identify potential compliance issues, and foster a clearer understanding of regulatory expectations.

By participating, companies can gain invaluable insights into the regulatory landscape for AI medical devices, ensuring their products meet the necessary standards for safety, performance, and ethical deployment. The structured yet flexible nature of the program, with its bespoke testing plans and rolling application process, provides a tailored pathway for innovation while maintaining regulatory rigor. This proactive approach is crucial for navigating the evolving complexities of AI medical device regulation and securing market access.

The long-term funding of the program until April 2029, coupled with the commitment to a subsequent shortlisting period in Spring 2027, signals the MHRA's sustained dedication to supporting the responsible development and integration of AI in healthcare. For manufacturers, this means a stable platform for addressing the AI enabled medical devices regulatory challenge, offering a unique chance to shape future regulatory frameworks through direct collaboration and real-world testing.

Lawyers advising clients developing AI-enabled medical devices should inform them about the MHRA's AI Airlock Phase 3, which offers a regulatory sandbox for testing and addressing compliance challenges, particularly in Post-Market Surveillance. This presents a crucial opportunity for early engagement with the regulator to de-risk product development and ensure future compliance.

Source: Original reporting via UK government guidance